Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) aims to optimize its asset structure and improve the quality of asset operations by transferring part of its accounts receivable through a public listing [1] Group 1: Asset Transfer Details - The company plans to transfer accounts receivable with a total book balance of 489.784 million yuan as of the assessment benchmark date of September 30, 2025 [1] - Bad debt provisions amount to 459.7945 million yuan, resulting in a book value of 29.9895 million yuan for the receivables being transferred [1] - The asset transfer is expected to enhance the company's operational development and protect the legal rights of the company and all shareholders [1] Group 2: Transaction Process - The transaction will be conducted through a public listing, and no transaction agreement has been signed yet [1] - It is currently unclear whether the transaction will constitute a related party transaction [1] - If the determined buyer through the public listing process is a related party, the company will follow the necessary review procedures for related party transactions [1]

Core Viewpoint - The company, through its subsidiaries, is participating in a national centralized procurement process for pharmaceuticals, which could enhance its market share and brand influence if selected products are confirmed and contracts are signed [1] Group 1: Company Participation - The company’s wholly-owned subsidiaries and a controlling subsidiary are involved in the national centralized procurement for expiring drug agreements [1] - The procurement office announced the proposed selection results for the procurement on February 10, 2026 [1] Group 2: Potential Impact - If the proposed selected products are confirmed and contracts are signed, it will help the company expand sales of related products [1] - The successful procurement will ensure that medical institutions prioritize the selected drugs, which is expected to positively impact the company's future operating performance [1]

Core Viewpoint - Huatai Technology (603679.SH) announced a share reduction by one of its actual controllers, Wang Shaorong, through block trading, resulting in a change in shareholding percentage due to capital changes from convertible bond conversions [1] Group 1 - Wang Shaorong reduced her shareholding by 1.916 million shares between February 6, 2026, and February 10, 2026 [1] - Following the reduction and the impact of convertible bond conversions, the combined shareholding percentage of Wang Shaorong and her concerted parties decreased from 33.80% to 32.55% [1] - The change in equity holding triggered a shift that touched the 1% threshold [1]

注射用青霉素钠适用于敏感菌所致的各类感染，如脓肿、菌血症、肺炎和心内膜炎。其中青霉素为以下 感染的首选药物：溶血性链球菌感染；肺炎链球菌感染；不产青霉素酶葡萄球菌感染；炭疽；破伤风、 气性坏疽等梭状芽孢杆菌感染；梅毒（包括先天性梅毒）；钩端螺旋体病；回归热；白喉；青霉素与氨 基糖苷类药物联合用于治疗草绿色链球菌心内膜炎。 格隆汇2月11日丨白云山(600332.SH)公布，公司控股子公司广州白云山天心制药股份有限公司（称"天 心制药"）收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，注射用青霉素钠0.96g （160万单位）已通过仿制药质量和疗效一致性评价。 ...

格隆汇2月11日丨科瑞技术(002957.SZ)公布，新加坡科瑞技术计划通过集中竞价、大宗交易等深圳证券 交易所认可的合法方式减持公司股份。新加坡科瑞技术计划减持不超过420万股，即不超过公司总股本 的1.0004%。 李单单女士计划通过集中竞价方式减持公司股份。李单单女士计划减持不超过12.42万股，即不超过公 司总股本的0.0296%。 饶乐乐先生计划通过集中竞价方式减持公司股份。饶乐乐先生计划减持不超过6万股，即不超过公司总 股本的0.0143%。 华苗投资计划通过集中竞价、大宗交易等深圳证券交易所认可的合法方式减持公司股份。华苗投资计划 减持不超过420万股，即不超过公司总股本的1.0004%。 鹰诺投资计划通过集中竞价、大宗交易等深圳证券交易所认可的合法方式减持公司股份。鹰诺投资计划 减持不超过400万股，即不超过公司总股本的0.9528%。 ...

格隆汇2月11日丨东南网架(002135.SZ)公布，近日收到招标单位杭州萧山城市有机更新有限公司发来的 《中标通知书》，确定公司与杭州市建筑设计研究院股份有限公司组成的联合体为"杭政储出（2025） 101号商业综合体新建项目EPC工程总承包项目"的中标单位。本项目中标总金额为人民币4.84亿元。 ...

Group 1 - The core point of the article is that Okoyi (688308.SH) announced a plan for its shareholder, Leqing Dehui, to reduce its stake in the company by up to 1.00% of the total shares, which amounts to a maximum of 1.58 million shares [1] - The share reduction will take place within three months after the announcement, starting 15 trading days from the date of disclosure [1] - The reduction will be executed through centralized bidding, with a limit that the total number of shares sold in any consecutive 90-day period does not exceed 1% of the company's total shares [1]

Group 1 - The company plans to acquire 70% equity of Huilian Electronics for no more than RMB 700 million, aiming to gain control over the company [1] - The funding for the acquisition will come from the company's own funds and merger loans [1] - The company also intends to acquire 70% equity of WINWIN HITECH (THAILAND) CO., LTD. for no more than RMB 28 million to address competition issues and develop overseas markets [1] Group 2 - Huilian Electronics specializes in PCB tools, cutting tools, and precision parts, recognized as a national-level "little giant" in the PCB tool sector and a champion enterprise in Henan province [2] - The acquisition will include PCB tools and related assets, with the major shareholders cooperating to divest non-PCB tool business assets [2] - This transaction is a strategic move to enhance the company's comprehensive layout in cutting tools and accelerate the domestic substitution of PCB tools, strengthening the integration of the hard alloy industry chain [2]

Group 1 - The company, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., and its subsidiary, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., have participated in the national centralized procurement for the continuation of products from the first to eighth batches, with results published on February 10, 2026 [1] - A total of 24 products, including Cefuroxime Sodium Injection and Clindamycin Phosphate Injection, are proposed to be selected for this procurement, which will last until December 31, 2028 [1] - The procurement volume will be based on the demand reported by medical institutions, with pricing determined by a tiered selection process [1] Group 2 - The total projected sales revenue for the selected products in 2024 is approximately RMB 798.19 million, accounting for 1.06% of the company's total revenue for that year [2] - For the first three quarters of 2025, the projected sales revenue is around RMB 550.45 million, representing 0.89% of the company's revenue during that period [2] - If contracts are signed and implemented, it is expected to further increase product sales, enhance market share, and improve the company's brand image, positively impacting future business development [2]

Core Viewpoint - The company has decided to terminate the capital increase and equity restructuring plan for its wholly-owned subsidiary due to changes in the internal and external environment, aiming to mitigate financial assistance risks and protect the integrity and safety of its business operations and investor interests [1] Group 1 - The company held the 11th meeting of the 7th Board of Directors to review and approve the termination of the capital increase and equity restructuring plan [1] - The decision was made after a careful assessment of the risks associated with potential financial assistance arising from the transaction [1] - The company signed a termination agreement with all parties involved to formalize the decision and ensure compliance with domestic and international circumstances [1] Group 2 - Following the termination of the transaction, the target company will remain a wholly-owned subsidiary of the company, ensuring no external financial assistance will be created [1] - The move is intended to safeguard the company's business integrity and maintain the controllability and safety of its funds [1] - The decision reflects the company's commitment to protecting the interests of its investors amidst changing market conditions [1]